newsfilter
← Latest News
GlobeNewswire·

Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric or Gastroesophageal Junction Cancer

All three efficacy endpoints in the global Phase 2 FIGHT trial met pre-specified statistical significance• Median progression-free survival (PFS) improved from 7.4 months in the placebo arm to 9.5...